http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
지역 약사의 자발적 부작용 보고에 대한 인식 및 태도와 영향요인 조사: 설문조사 결과를 중심으로
이모세,최아형,장보현,김나영,이정민,신주영,전하림 한국임상약학회 2019 한국임상약학회지 Vol.29 No.2
Objective: To examine the perceptions and attitudes toward spontaneous adverse drug reaction (ADR) reporting system among community pharmacists and identify factors that influence reporting, by implementing a survey. Methods: A structured questionnaire was developed and distributed online. Request for the survey was posted on the website of pharmacy’s billing program, and the survey was conducted for 8 days. We collected the participants’ response on their work environment, experience of ADR reporting, and their perception and attitude on the reporting system. Multivariate logistic regression was used to evaluate factors influencing ADR reporting. Results: A total of 382 pharmacists participated in the survey. Significant contributing factors for reporting level were age (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.84-0.96), knowledge of reporting method (OR, 53.56; 95% CI, 9.10-315.41), installation of reporting program (OR, 31.92; 95% CI, 4.16-244.75), and encouragement from the Korean pharmaceutical association (OR, 4.13; 95% CI, 1.11-15.35). Regarding the attitude toward spontaneous ADR reporting system, ‘lack of time for reporting’ (OR, 0.29; 95% CI, 0.15-0.53) and ‘complexity of reporting procedure’ (OR, 0.51; 95% CI, 0.31-0.84), were associated with a low likelihood of reporting. Conclusion: Our results indicated that the knowledge of ADR reporting method, installation of the reporting program, and encouragement from the Korean Pharmaceutical Association contribute to active reporting. It is necessary to simplify the reporting method, make the ADR reporting program user-friendly, and provide educational interventions to increase participation in spontaneous reporting by the community pharmacists.
해외 주요국의 환자 약물사용 관리 및 모니터링 제도 운영현황
전하림,배성호,최아형,윤동원,이혜성,신주영 한국보건사회약료경영학회 2022 한국보건사회약료경영학회지 Vol.10 No.1
OBJECTIVES To investigate government programs or policies that aim to manage and monitor drug use in patients in foreign countries. METHODS We conducted a literature review by searching electronic documents through domestic literature databases, various search engines, and official websites of public organizations or government-related agencies in charge of programs or policies. The contents of investigation included the purpose of the program, how to operate, eligible patients or drug class, action by physicians or pharmacists, and rewards for participation. RESULTS We identified national or regional programs for rational and safe use of drug in patients in 6 countries. The UK implemented ‘Medical Use Review’ and ‘New Medicine Service’ as a pharmacist’s service and ‘High Risk Drug Monitoring’ as a general practitioner’s service. In Ontario, Canada, ‘MedsCheck’ programs encourage pharmacists to manage drug therapy of patients. ‘Long-Term Condition service’ in New Zealand consisted of pharmacist’s services for patients who received prescriptions for multiple long-term conditions and had adherence issues. The US has the ‘Medication Therapy Management’ program that includes a review of prescription history, evaluation of drug therapy, and patient counseling. CONCLUSION Various programs for drug use management were being operated in accordance with the public health system of each country. A comprehensive program for appropriate and safe drug use in patients is also needed in Korea.
건강보험청구자료를 이용한 HER2 양성 전이성 유방암 환자의 조기 사망에 따른 간접적 질병 부담 분석
고화연(Hwa Yeon Ko),최아형(Ahhyung Choi),홍빈(Bin Hong),배지환(Ji-Hwan Bae),오인선(In-Sun Oh),박선경(Sun-Kyeong Park),박연희(Yeon Hee Park),신주영(Ju-Young Shin) 대한약학회 2023 약학회지 Vol.67 No.3
The premature deaths caused by human epidermal growth factor receptor-2 protein (HER2) positive metastatic breast cancer (MBC) among working age groups result in significant socioeconomic losses. This study aims to quantify the socioeconomic burden of disease in female patients and provide evidence that can inform healthcare policy decisions. We identified deaths from HER2-positive MBC over the period from 2007 to 2021, using nationwide claims data of South Korea. Then, we estimated years of potential life lost (YPLL), years of potential productivity lost (YPPLL), and cost of productivity loss (CPL) to quantify socioeconomic burden of the disease. During the period from 2011 to 2020, a total of 3,576 patients died from HER2-positive MBC. The total YPLL over the period of 10 years from 2011 to 2020 was 128,605 years, corresponding to an average of approximately 36.0 years per deceased patient. The total YPPLL during the same period was 55,608 years, corresponding to an average of approximately 15.6 years per deceased patient. Additionally, total CPL of approximately 310 million won per deceased patient was incurred. All three disease burden indicators were highest among the age group of 40 to 54 years, which are individuals in their most productive time of life.
DUR 제도 및 DUR 고도화 시범사업에 대한 인식 탐구 : 포커스 그룹 인터뷰 기법 중심의 질적 연구
배성호,전하림,윤동원,최아형,이혜성,신주영 한국임상약학회 2021 한국임상약학회지 Vol.31 No.2
Objective: To explore the perception of drug utilization review (DUR) system and DUR modernization pilot project among healthcare professionals and patients. Methods: We conducted 8 times of focus group interviews (FGI) between August 1, 2019 to December 31, 2019. The healthcare professionals and patients who participated in the DUR modernization pilot project were included in the present study. Based on the type of project participation or medical institution, the participants were divided into the following four groups: group 1, hospital; group 2, clinic; group 3, pharmacy; and group 4, patient. Within each group, interviews were conducted under a pre-defined agenda to identify the implicit perceptions of the participants; the contents of the interviews were, then, categorized. Results: Healthcare professionals established a consensus on the positive aspects of the DUR system and DUR modernization pilot project. However, substantial concerns remain, such as additional workload associated with monitoring adverse events or acquiring consents from patients. Furthermore, a difference of opinion over the DUR convenience system was observed. Among 3 DUR convenience system, the personal medication history review service was highly utilized, but pop-up hold function and communication system was rarely used. Conclusion: We observed that systematic intervention using the DUR system is effective for both healthcare providers and consumers. Adverse events caused by inappropriate drug use can be prevented by continuous patient monitoring. Therefore, the role of DUR system needs to be expanded to establish a safe drug management system.